E-DRUG: Oxfam statement at WHO Executive Board on the Roadmap to access to medicines
-------------------------------------------------------------------------------------------------
The roadmap defines WHO’ work on medicine providing a comprehensive ground
plan for WHO’ work during the period of 2019- 2023.
https://www.who.int/medicines/access_use/Roadmap_for_access_zero_draft.pdf
Oxfam urges the WHO to emphasize the following points:
1. Aligning the milestones on intellectual property with the
recommendations of the Global Strategy and Plan of Action on IP and
innovation;
2. Integrating relevant recommendations from the report of the High
Level Panel on human rights and access to medicines;
3. Proactively promoting the use of the flexibilities enshrined in
the Trade related Aspects of Intellectual Property Rights agreement
(TRIPS);
4. Exploring incentives for biomedical innovation based on delinking
financing of R&D from the price of resulting products;
5. Ensuring transparency across the medicine chain starting from the
cost of R&D, the results of clinical trials and the prices of medicines in
order to make effective medicines and health technologies affordable for
health systems.
Oxfam urges member states to provide strong political support to recommend
the roadmap for WHA approval. Member states also need to ensure that the
roadmap is fully funded in order for the WHO to be able to support
countries to scale up access to affordable quality medicines, vaccines and
health technologies.
Achieving Universal Health Coverage depends on access to affordable
quality medicines. The implementation of the WHO roadmap is critical for
countries to achieve UHC and the SDGs targets on access to medicines.
Thank you
Best wishes from Geneva
Dr. Mohga Kamal-Yanni
Senior health & HIV policy advisor, Oxfam GB
Editor of www.globalhealthcheck.org
John Smith Drive, Oxford, UK Mobile
Mohga Kamal-Yanni <mkamalyanni@Oxfam.org.uk>